Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]F-AraG PET Imaging in NSCLC
NCT04524195Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluorine f 18 ara-g in non-small cell lung cancer (NSCLC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Percent Change in uptake of [18F]F-AraG and Percent pathologic response. Started Feb 2021; status: terminated.
02
Drugs
fluorine f 18 ara-g
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04524195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524195.